Literature DB >> 24684674

Interferon lambda-2 levels in sputum of patients with pulmonary Mycobacterium tuberculosis infection.

M Travar1, M Vucic, M Petkovic.   

Abstract

In humans, there are three members of type III interferon family, designated as IFN-λ1 (IL-29), IFN-λ2 (IL-28A) and IFN-λ3 (IL-28B). Bacterial infections, including Mycobacterium tuberculosis infection, trigger the expression of interferon I and II genes, but little is known about their effect on IFN-λ genes. It has been found that M. tuberculosis infection in A549 lung epithelial cells stimulate upregulation of IFN-λ2 genes in vitro. The aim of this study was to determine the IFN-λ2 levels in sputum of patients with active pulmonary tuberculosis comparing with levels in healthy persons sputum and sputum of persons with latent tuberculosis. IFN-λ2 level in the samples was quantified with sandwich enzyme-linked immunoassay kit for quantization of human IFN-λ2 (IL-28A). The IFN-λ2 level in sputum of patients with pulmonary tuberculosis was significantly higher comparing with IFN-λ2 levels in healthy group (P = 0.001) and latent tuberculosis group (P = 0.005). Logistic regression analysis has shown that IFN-λ2 level in sputum is related to culture result (OR = 4.14; 95% CI = 1.28-17.5; P = 0.019). There was the correlation between Bartlett score and IFN-λ2 levels in group with pulmonary tuberculosis (r = 0.641; P < 0.01). In conclusion, we have found that the inflammatory cells in sputum can be source of IFN-λ after receptor stimulation by M. tuberculosis components.
© 2014 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24684674     DOI: 10.1111/sji.12178

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  10 in total

Review 1.  Type III IFNs: Beyond antiviral protection.

Authors:  Sergei V Kotenko; Amariliz Rivera; Dane Parker; Joan E Durbin
Journal:  Semin Immunol       Date:  2019-06       Impact factor: 11.130

2.  Sputum endothelin-1 level is associated with active pulmonary tuberculosis and effectiveness of anti-tuberculosis chemotherapy.

Authors:  Xiang Wang; Jingqun Tang; Ranran Wang; Chen Chen; Shichuan Tan; Fenglei Yu; Yongguang Tao; Yunping Li
Journal:  Exp Ther Med       Date:  2016-01-11       Impact factor: 2.447

Review 3.  Interferon-λ: Immune Functions at Barrier Surfaces and Beyond.

Authors:  Helen M Lazear; Timothy J Nice; Michael S Diamond
Journal:  Immunity       Date:  2015-07-21       Impact factor: 31.745

Review 4.  Microbial pathogenesis and type III interferons.

Authors:  Taylor S Cohen; Dane Parker
Journal:  Cytokine Growth Factor Rev       Date:  2016-03-04       Impact factor: 7.638

Review 5.  Role of Interferons in the Development of Diagnostics, Vaccines, and Therapy for Tuberculosis.

Authors:  Kai Ling Chin; Fadhilah Zulkipli Anis; Maria E Sarmiento; Mohd Nor Norazmi; Armando Acosta
Journal:  J Immunol Res       Date:  2017-06-20       Impact factor: 4.818

Review 6.  Interferon Lambda: Modulating Immunity in Infectious Diseases.

Authors:  Mohammedyaseen Syedbasha; Adrian Egli
Journal:  Front Immunol       Date:  2017-02-28       Impact factor: 7.561

7.  Interferon-λ3 Promotes Epithelial Defense and Barrier Function Against Cryptosporidium parvum Infection.

Authors:  Sylvia H Ferguson; Derek M Foster; Barbara Sherry; Scott T Magness; Dahlia M Nielsen; Jody L Gookin
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2019-03-05

Review 8.  Gene-disease association with human IFNL locus polymorphisms extends beyond hepatitis C virus infections.

Authors:  S Chinnaswamy
Journal:  Genes Immun       Date:  2016-06-09       Impact factor: 2.676

Review 9.  Immunosuppressive Mechanisms in Brucellosis in Light of Chronic Bacterial Diseases.

Authors:  Joaquin Miguel Pellegrini; Jean-Pierre Gorvel; Sylvie Mémet
Journal:  Microorganisms       Date:  2022-06-21

10.  Macrophages and neutrophils express IFNλs in granulomas from Mycobacterium tuberculosis-infected nonhuman primates.

Authors:  Priyanka Talukdar; Beth F Junecko; Daniel S Lane; Pauline Maiello; Joshua T Mattila
Journal:  Front Immunol       Date:  2022-09-13       Impact factor: 8.786

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.